Introduction Many treatment regimens have been evaluated in transplant-ineligible (TIE)
patients with newly diagnosed multiple myeloma (NDMM). The objective of this study was to …

Objectives Multiple myeloma (MM) is a complex disease. Lack of direct comparisons among
treatments and incorporation of new alternatives make it necessary to perform studies that …

Background Despite major therapeutic advances, the rational choice of the most appropriate
first-line regimen in newly diagnosed transplant-ineligible multiple myeloma (TIE-MM) is …

Choice of treatment for newly diagnosed transplant-ineligible multiple myeloma poses a
difficult task due to an ever-increasing plethora of different regimens. Attempting to clarify …

Many new regimens have been applied to newly diagnosed transplant-ineligible multiple
myeloma, but no head-to-head research has been performed to compare the efficacy of …

Decision making for patients with multiple myeloma (MM) not transplant eligible (NTE) is
complicated by a lack of head-to-head comparisons of standards of care, the increase in the …

Background Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell
transplantation is standard treatment in Europe for transplant-eligible patients with newly …

Introduction: Despite recent treatment (tx) advances that have improved overall survival
(OS), multiple myeloma (MM) remains a mostly incurable malignancy. Txs become less …

Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell
transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with …

Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/
dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly …